Pausing immunotherapy for advanced cancer guided by a blood test
Part of Cancer, Digestive system, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This trial tests whether people with advanced cancer who have responded well to immunotherapy can safely pause their treatment, guided by a blood test that looks for cancer DNA. If the blood test stays clear, you might be able to take a break from treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have advanced or metastatic cancer, such as melanoma, lung cancer, colorectal cancer, kidney cancer, or another solid tumor.
- You have been on immunotherapy (like a PD-1 or CTLA-4 inhibitor) for at least 6 to 15 months, depending on your cancer type.
- Your last scan showed that your cancer shrank or disappeared (complete or partial response).
- You have had at least two negative blood tests for cancer DNA, spaced at least 6 weeks apart, with the last one within a month of starting the study.
- You are generally in good health (able to do daily activities, with some limitations allowed).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at using a blood test that detects tiny pieces of cancer DNA (called ctDNA) to help decide how long patients with advanced melanoma should stay on immunotherapy. It may help some patients safely stop treatment earlier if the blood test shows the cancer is under control.
This trial is testing a simple blood test (using white blood cells) to see if it can predict how well immunotherapy will work for people with advanced cancer. If you are starting immunotherapy soon as your first treatment, this study might help guide your care.
This study looks at how your body reacts to checkpoint inhibitors (immunotherapy drugs like Keytruda or Opdivo) for NSCLC. It involves blood tests to check for antibodies your immune system might make against the drug.
This study looks at a simple blood test to see if it can predict how well your cancer will respond to immunotherapy. You will give blood samples before and during treatment, and the researchers will analyze small particles in your blood to find clues about your likely response.
This study is looking at whether a special PET scan (FDG PET/CT) and a blood test that measures ctDNA (cancer DNA in the blood) can help predict how well immune checkpoint inhibitors work in people with advanced melanoma. If you are planning to get treatment with immunotherapy drugs like ipilimumab, nivolumab, or pembrolizumab, you may be able to join.
This trial tests whether using a blood test (Signatera) to guide treatment can safely reduce the amount of chemotherapy after surgery for stomach or esophagus cancer. The goal is to see if less treatment is just as effective, based on whether cancer DNA is still detectable in your blood.
Hear when a new NSCLC (Advanced Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.